Rottenstein Law Group Reports on FDA Caution About Long-Term Use of Fosamax and Similar Bone Drugs
The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, has learned that the FDA has published an analysis generally recommending caution when using popular bone-building medications for long terms, though without offering more specific suggestions. New York, NY (PRWEB) May 14, 2012 The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, has learned that the FDA has published an analysis generally recommending caution when using popular bone-building medicat
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 313
- Bankruptcy 44
- Business 135
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4